Clinical efficacy and safety of a beta3-adrenoceptor agonist and an antimuscarinic agent in female patients with overactive bladder: a randomized crossover study

Trial Profile

Clinical efficacy and safety of a beta3-adrenoceptor agonist and an antimuscarinic agent in female patients with overactive bladder: a randomized crossover study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Mirabegron (Primary) ; Imidafenacin
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms MICRO
  • Most Recent Events

    • 09 Oct 2015 Status changed from recruiting to active, no longer recruiting according to results presented at the 45th Annual Meeting of the International Continence Society
    • 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
    • 25 Aug 2015 Planned End Date changed from 31 Mar 2015 to 31 Aug 2015, according to UMIN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top